stockportfolio.pro
Stocks / BLCO vs COGT
BLCO vs COGT
Bausch + Lomb Corporation and Cogent Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bausch + Lomb Corporation (BLCO) | Cogent Biosciences, Inc. (COGT) | |
|---|---|---|
| Market cap | $5.4B | $5.5B |
| Revenue (latest FY) | $5.10B | $0 |
| Net income (latest FY) | $-360.00M | $-328.94M |
| Revenue growth (5y CAGR) | 8.4% | — |
| Net margin | -7.1% | — |
| Return on equity | -5.6% | -51.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLCO — free Open COGT — freeFrequently asked questions
Which is bigger, BLCO or COGT?
Cogent Biosciences, Inc. is larger by market capitalization — $5.5B versus $5.4B.
Which grows faster, BLCO or COGT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.